



Advances in Antifungal Therapies: Miconazole Roll-On Gel as a Convenient Topical Solution

Devika Sahu², Monika Sahu¹, Rupesh Pal¹, Minakshi², Priyanshu Dewangan¹, Sobha Sahu¹, Harish Sharma³ and Gyanesh Kumar Sahu^{1*}

¹Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India

²Rungta Institute of Pharmaceutical Sciences, Kohka, Kurud, Bhilai, India

³School of Pharmacy, Anjaneya University, Raipur, India

*Corresponding Author: Dr. Gyanesh Kumar Sahu, Professor and Dean, Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India.

Received: December 04, 2024

Published: December 24, 2024

© All rights are reserved by

Gyanesh Kumar Sahu., *et al.*

Abstract

Fungal infections pose significant challenges due to their prevalence and resistance to conventional treatments. Miconazole, an azole antifungal agent, is widely recognized for its broad-spectrum activity against dermatophytes, yeasts, and molds. However, conventional formulations such as creams and ointments often suffer from issues like inconsistent application, poor patient compliance, and reduced efficacy due to limited retention on affected areas.

This review explores the potential of miconazole roll-on gel as a novel, user-friendly formulation for effective antifungal therapy. The roll-on gel format offers benefits such as ease of application, enhanced penetration, and prolonged retention at the infection site, leading to improved therapeutic outcomes. The formulation considerations, including gelling agents, drug release profiles, and stability studies, are discussed in detail.

Moreover, the review examines preclinical and clinical studies evaluating the efficacy, safety, and patient acceptability of the miconazole roll-on gel compared to conventional formulations. It also highlights the challenges in the development process, such as achieving uniform drug distribution and overcoming formulation stability issues.

The findings indicate that miconazole roll-on gel has the potential to improve antifungal treatment outcomes by addressing limitations of traditional delivery systems. This review aims to provide insights into its development and to encourage further research in innovative topical drug delivery methods for antifungal therapies.

Keywords: Onychomycosis; Clotrimazole; Miconazole

Introduction

Fungal infections, caused by dermatophytes and yeasts, are a widespread global health concern, particularly in warm, humid environments that favor fungal growth. These infections, commonly affecting the skin, hair, and nails, include conditions like Tinea Pedis (Athlete's Foot), Tinea Corporis (Ringworm), and Onychomycosis (nail infections) [1,2]. While not life-threatening in most cases, these infections can cause significant discomfort, itching, and social embarrassment, impacting the quality of life. Superficial fungal infections are highly contagious and thrive in communal environments like swimming pools, gyms, and locker rooms, making prevention and effective treatment essential [3,4].

Among antifungal treatments, azole drugs such as clotrimazole, miconazole, and ketoconazole are widely used for their efficacy and safety. These drugs inhibit ergosterol synthesis, a vital component of fungal cell membranes, leading to the disruption of fungal growth. Miconazole, in particular, is known for its broad-spectrum activity against dermatophytes and yeasts. Its availability in various formulations, including creams, powders, and gels, makes it versatile for treating different fungal infections [5,6]. The development of a roll-on gel formulation for miconazole further enhances its utility, offering easy application, targeted delivery, and hygienic use, especially for areas like the feet and groin.

A common broad-spectrum antifungal medication used to treat a variety of mucosal and superficial fungal infections is miconazole. Miconazole, a member of the azole antifungal class, works by preventing the production of ergosterol, which is essential for the formation of fungal cell membranes. Miconazole is a successful treatment for a variety of dermatophyte and yeast infections because it causes fungal cell death through a breakdown in the integrity of the cell membrane [7,8].

The medication is available in creams, powders, sprays, vaginal suppositories, and oral gels, and its effectiveness is extended to both topical and systemic formulations. Miconazole is a well-liked option for treating mild to moderate fungal infections in outpatient settings due to its accessibility and adaptability [9,10].

Apart from its well-established medicinal use, miconazole is renowned for having a comparatively low frequency of adverse effects, however skin irritation and, in rare cases, systemic reactions are possible. Due to its safety profile, the medication is now widely used for both clinical treatment of fungal infections and self-care. Despite its wide range of applications, further consideration of its efficacy and use is necessary due to the development of drug resistance in certain fungal strains and the possibility of medication interactions, especially with oral anticoagulants [11,12].

History

A breakthrough in azole antifungal therapy led to the initial development of miconazole, an imidazole antifungal drug, in the early 1970s. It first appeared at a period when fungal infections were becoming more widely acknowledged as a serious health risk, especially for people with weakened immune systems. Miconazole's broad-spectrum action against dermatophytes, yeasts like *Candida*, and some Gram-positive bacteria led to its widespread acceptance [13,14]. Originally developed as topical creams, powders, and oral gels, it proved effective in treating a range of mucocutaneous and superficial fungal infections. Miconazole's method of action, which targets the synthesis of fungal ergosterol, making it a safer substitute for older antifungal drugs with higher toxicity profiles, such as amphotericin B. Miconazole has developed into a reliable antifungal throughout time and is now widely accessible in both prescription and over-the-counter medications [12].




Figure 1: History of Antifungal drug Development.

Miconazole's roll-on gel formulation is a contemporary development that overcomes the drawbacks of conventional delivery systems like creams and ointments. Initially, roll-on gels were investigated as a means of improving patient compliance, ensuring accurate dose, and making application easier. Roll-on applicators' design reduces product waste, avoids contamination, and makes it easy to apply to difficult-to-reach places, including skin folds and intertriginous zones that are frequently impacted by fungal infections. The growing need for effective and user-friendly antifungal delivery systems is met by this breakthrough. In addition to expanding its therapeutic use, the addition of miconazole to a roll-on gel has given those looking for hygienic and portable treatment choices a solution [15,16].

Disease

Pathogenic fungi that infiltrate human tissues are the cause of fungal infections, often known as mycoses. These infections can range from superficial skin layers to deep systemic diseases. In tropical and subtropical regions, where heat and humidity foster the growth of fungi, these diseases are especially troublesome. Millions of people are afflicted with superficial fungal diseases every year, including dermatophytosis (ringworm), candidiasis, and pityriasis versicolor [17,18]. The quality of life is greatly impacted by these disorders, which mostly affect the skin, hair, and nails and are frequently characterized by symptoms like redness, itching, scaling, and discolouration. Because they are so persistent, cutaneous infections frequently need ongoing care to avoid recurrence [18,19].



Figure 2: Disease of Antifungal.

Conversely, systemic fungal infections such as invasive candidiasis and cryptococcosis provide serious health dangers, particularly to immunocompromised people like those receiving chemotherapy, organ transplants, or HIV/AIDS. Treatment options have become even more complex due to the increasing incidence of drug-resistant fungus pathogens. Because of its location, which is frequently made worse by moisture and friction, intertrigo, a fungal infection of skin folds, is one of the most difficult superficial fungal infections to treat. Applying conventional antifungal therapies, such as creams, in these locations might be challenging, resulting in insufficient coverage and less than ideal outcomes. For such infections, the roll-on gel formulation of miconazole provides a focused, practical approach that addresses patient comfort and therapeutic efficacy by guaranteeing even application, quick absorption, and enhanced adherence to treatment [19,20].

Types of fungal infections (mycoses) in detail

Miconazole roll-on gel is made especially to efficiently treat localized and superficial fungal infections. It can be used to treat the following kinds of fungal infections because of its targeted distribution and ease of application:

Tinea infections (Dermatophytosis)

Dermatophytes, a class of fungi that flourish in keratin-rich tissues like skin, hair, and nails, are the source of tinea infections, often referred to as dermatophytosis. These infections are often categorized according to the location and appearance of the lesions, and they can affect different regions of the body. Tinea Pedis (Athlete’s Foot), Tinea Corporis (Ringworm), Tinea Cruris (Jock Itch), Tinea Capitis (Scalp Ringworm), and Tinea Unguium (Onychomycosis) are common types of tinea infections. Direct contact with an infected individual or contaminated surfaces, such as floors, bedding, shoes, and towels, can spread these extremely contagious illnesses. Living in warm, humid conditions, not washing your hands

frequently, wearing clothing that is too tight or doesn’t breathe, and having a compromised immune system are all risk factors for getting these illnesses. Individuals [21,22].

Itching, burning, redness, and the development of rings or patches on the skin are the most typical signs of tinea infections. For instance, Tinea Corporis frequently manifests as a ring-shaped, scaly area with a clear core, whereas Tinea Pedis causes itching and peeling between the toes. Tinea Capitis causes itchy, scaly areas on the scalp, which frequently result in hair loss, while Tinea Cruris causes redness and irritation in the groin area. Inflammation, painful blisters, and sores can result from severe tinea infections. Topical antifungal medications, such as miconazole, which can be applied as creams, gels, or roll-on formulations, are commonly used in treatment. Oral antifungal drugs may be used in certain extreme circumstances. In addition to therapy, keeping appropriate [23,24].




Figure 3: Types of fungal infection in different body part.

Cutaneous mycoses

Fungal infections that affect the deeper layers of the epidermis, hair, and nails are known as cutaneous mycoses. Dermatophytes like Trichophyton, Microsporum, and Epidermophyton are the main culprits behind these infections. Although the skin is frequently the site of these infections, they can also spread to the scalp and nails. Inflammation, scaling, and other obvious symptoms are caused by dermatophytes, which feed on keratin, the protein found in skin, hair, and nails. Tinea Pedis (athlete’s foot), Tinea Corporis (ringworm), and Onychomycosis (nail infection) are common types of cutaneous mycoses. Peeling, redness, and severe itching, particularly between the toes, are symptoms of tinea pedis. Round,

ring-shaped red spots with elevated edges and a clear center are the outcome of tinea corporis. In contrast [26].

Inflammatory, scaly lesions that can be uncomfortable and itchy are typically the hallmark of cutaneous mycoses' symptoms. In addition to pain, nail infections can cause thickening or brittleness in the afflicted nails, which frequently results in the nail pulling away from the nail bed. Topical antifungal medications such as miconazole gel, which target the fungal infection directly on the skin, are an effective treatment for mild cases of cutaneous mycoses. Oral antifungal drugs like terbinafine or itraconazole may be recommended for more severe infections, such as Onychomycosis or widespread fungal skin infections. To lower the chance of transmission and recurrence, antifungal therapies should be used in conjunction with proper hygiene, drying out the afflicted regions, and refraining from exchanging personal belongings.

Dosage forms of antifungal treatments

Different dosage types of antifungal treatments are available, each of which is customized to the patient's preferences, the place of the illness, and its severity. Topical preparations, which transport the active antifungal agent directly to the affected site, are the most often used dosage forms for treating cutaneous mycoses, which include disorders like Tinea Pedis, Tinea Corporis, and Onychomycosis. For mild to severe fungal infections, topical creams, gels, ointments, sprays, and powders are frequently utilized. These forms are perfect for localized infections since they are practical, simple to use, and have little systemic absorption. An additional convenience is offered by a roll-on gel antifungal treatment, like miconazole roll-on gel, which offers a targeted, mess-free delivery method. The gel is uniformly applied throughout the afflicted area thanks to the roll-on application.

Oral antifungal medications are frequently used for more severe or recalcitrant infections, especially those that affect the nails or deeper layers of the epidermis. Infections that are difficult to treat with topical therapies alone are frequently treated with medications such as terbinafine, itraconazole, and fluconazole. Oral drugs are absorbed systemically and function by preventing the fungus from growing from inside the body, frequently penetrating deeper layers of the skin, hair, and nails. When the illness has spread or is not responding to topical therapies, these types of

treatment are usually utilized for onychomycosis or tinea capitis (scalp infections). The degree of infection, patient characteristics including age and comorbidities, and the pharmacokinetics and efficacy of the particular antifungal medication all influence the dose form selection.

New antifungal drugs

A number of azole antifungal medications have been created to treat cutaneous mycoses and other fungal infections; some of the more popular and efficient ones include clotrimazole, miconazole, and ketoconazole. By preventing the production of ergosterol, a crucial part of the fungal cell membrane, these medications cause structural and functional abnormalities in the cell, which ultimately results in the fungal cell's demise. Tinea Pedis, Tinea Corporis, Tinea Cruris, and Candidiasis are among the fungal infections that can be treated with these medications, each of which has special properties.

Clotrimazole

Topical preparations of the broad-spectrum antifungal drug clotrimazole are frequently used to treat superficial fungal diseases such as ringworm, jock itch, and athlete's foot. Because of its minimal systemic absorption, it is perfect for localized treatment and comes in creams, lotions, and lozenges. Clotrimazole can be used to treat a variety of fungal diseases since it works against both dermatophytes (like Trichophyton and Epidermophyton) and yeasts (like Candida species). The medication's broad use in clinical practice is a result of its capacity to treat both skin and mucosal infections, including vaginal and oral candidiasis.

Ketoconazole

Another strong azole antifungal, miconazole, is frequently found in topical formulations such as roll-on gels, creams, gels, and powders. Athlete's foot, ringworm, and jock itch are among the dermatophyte and yeast infections that it effectively treats. The benefit of miconazole is its comparatively lengthy half-life, which permits less frequent administration (once or twice daily), improving patient adherence. It is frequently utilized in over-the-counter medications for the treatment of superficial fungal infections and has a high degree of safety. The antifungal qualities of miconazole are also present in systemic preparations, especially for severe cases of candidiasis.

Patents

| S. No | Author | Title | Patent Number | Submission | Publication | Reference no. |
|-------|--|--|----------------|------------|-------------|---------------|
| 1. | Shao xiang Lu, Jeffrey lu, Letian Liu, | Reversely thermos-reversible Hydrogel Compositions | US8865143B2 | 2012-03-21 | 2014-10-21 | [31] |
| 2. | Kennth E. Stockman, Mark W. Grinstaff, | Crosslinked gel comprising polyalkyl-eneimines and their use as medical device | CA2635374C | 2007-01-11 | 2015-12-08 | [32] |
| 3. | Markus Gewehr,Tatjana Sikuljak | Agricultural mixtures comprising carboxamide compound | EP3057419B1 | 2014-10-16 | 2021-07-28 | [33] |
| 4. | John Ridden, Michael Davies | Antifungal Topical compositions and methods of treatment | EP3049056B2 | 2014-09-25 | 2022-06-21 | [34] |
| 5. | Charless G. VONTZ | Antifungal Formulation | US8362059B2 | 2011-08-19 | 2013-01-29 | [35] |
| 6. | C.Steven MC Daniel | Antifungal paints and coating | US8497248B2 | 2011-04-19 | 2013-07-30 | [36] |
| 7. | Modassir CHODHRY | Tumor infiltrating Lymphocytes and methods of therapy | AU2017346885B2 | 2017-10-18 | 2021-10-21 | [37] |
| 8. | Joseph Charles Sal-amone, Xiaoyuchen, | Delivery of biologically active agent using volatile hydrophobic solvent | EP29168020B1 | 2013-10-21 | 2023-10-11 | [38] |
| 9. | John olin Trimble | Antifungal treatment of nails | US8333981B2 | 2008-10-06 | 2012-12-18 | [39] |
| 10. | Shamik GHOSH, Sumana GHOSH | Synergistic antifungal compositions and method thereof | EP3468544A2 | 2017-06-13 | 2019-04-17 | [40] |

Table 1

Future prospects

Because of continuous improvements in drug delivery systems and combination therapy, the future of antifungal medicines, such as medications like clotrimazole, miconazole, and ketoconazole, is quite promising. The penetration of these antifungals into difficult-to-reach places like the scalp and nails is anticipated to be improved by new technologies like nanoencapsulation and microsphere-based delivery, increasing their effectiveness and lowering the frequency of treatments. Roll-on gels and creams are examples of topical formulations that may gain popularity because they provide targeted therapy with less systemic side effects. Furthermore, azole antifungals may improve treatment results when combined with other therapeutic agents like steroids or anti-inflammatory medications, particularly when treating infections that are resistant or linked to severe inflammation.

The discovery of novel antifungal medicines will be essential as fungus resistance becomes a greater concern. Treatments for resistant fungal strains may become more effective with the development of new types of antifungal medications and research into novel molecular targets. Another intriguing approach is personalized medicine, where biomarkers and genetic tests can be used to customize antifungal therapy for specific individuals, guaranteeing more accurate and efficient care. The future of antifungal

treatments is anticipated to be reshaped by these developments, in addition to ongoing research into combination therapy and sophisticated formulations, which will address present issues and enhance patient care over time.

Clinical trial

Miconazole is a common antifungal drug that works well against a variety of fungal infections, such as those brought on by molds, yeasts, and dermatophytes. To compare the effectiveness, safety, and patient compliance of a novel miconazole roll-on gel formulation to conventional antifungal therapies, a clinical investigation was carried out. To assess the tolerance of treatments for fungal infections, antifungal therapy is crucial.

These studies frequently focus on invasive fungal diseases (such as invasive aspergillosis and candidemia) that impact immunocompromised people as well as superficial infections (like athlete's foot, ringworm, and candidiasis).

Miconazole is a popular antifungal drug that works well against yeasts, dermatophytes, and some types of mold. To increase application ease, patient compliance, and treatment effectiveness for superficial fungal infections, a new roll-on gel formulation was created [27-36].

Conclusion

To sum up, the treatment of common fungal infections like Tinea Pedis, Tinea Corporis, and Onychomycosis has greatly improved with the development and application of antifungal medications like clotrimazole, miconazole, and ketoconazole. Because of their efficacy and minimal chance of systemic side effects, these agents—especially in their topical formulations remain essential for treating superficial infections. The future of antifungal therapy, however, will rely on advancements in drug delivery methods, combination treatments, and the development of new antifungal drugs as fungus resistance increases. Antifungal medications will continue to advance in response to new problems in clinical and community settings thanks to the promise of personalized medicine and targeted therapies in improving treatment outcomes.

Bibliography

1. Amanlou Massoud., et al. "Miconazole gel compared with Zataria multiflora Boiss. gel in the treatment of denture stomatitis". *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives* 20.11 (2006): 966-969.
2. Loreto Erico S and Juliana SM Tondolo. "Introductory Chapter: Epidemiology of Invasive Fungal Infection-An Overview". *Fungal Infection* (2019).
3. Richardson Malcolm D and David W Warnock. "Fungal infection: diagnosis and management". John Wiley and Sons, (2012).
4. Sanguinetti M., et al. "Diagnosis and treatment of invasive fungal infections: looking ahead". *Journal of Antimicrobial Chemotherapy* 74 (2019): ii27-ii37.
5. Fothergill AW. "Miconazole: a historical perspective". *Expert Review of Anti-infective Therapy* 4.2 (2006): 171-175.
6. Piérard GE., et al. "Miconazole, a pharmacological barrier to skin fungal infections". *Expert Opinion on Pharmacotherapy* 13.8 (2012): 1187-1194.
7. Ansari S and Prasad R. "Effect of miconazole on the structure and function of plasma membrane of *Candida albicans*". *FEMS Microbiology Letters* 114.1 (1993): 93-98.
8. Shadomy S., et al. "In vitro studies with miconazole and miconazole nitrate". *Journal of Antimicrobial Chemotherapy* 3.2 (1977): 147-152.
9. Zhang L W., et al. "Efficacy and safety of miconazole for oral candidiasis: a systematic review and meta-analysis". *Oral Diseases* 22.3 (2016): 185-195.
10. Mohan M., et al. "Management of human keratomycosis with miconazole". *Australian and New Zealand Journal of Ophthalmology* 17.3 (1989): 295-297.
11. Capistrano H M., et al. "Brazilian green propolis compared to miconazole gel in the treatment of *Candida*-associated denture stomatitis". *Evidence-Based Complementary and Alternative Medicine* 1 (2013): 947980.
12. Regidor PA., et al. "Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature". *Journal of Obstetrics and Gynaecology* 43.1 (2023): 2195001.
13. Foster CS. "Miconazole therapy for keratomycosis". *American Journal of Ophthalmology* 91.5 (1981): 622-629.
14. Graybill J R. "The future of antifungal therapy". *Clinical Infectious Diseases* 22 (1996): S166-S178.
15. Espinel-Ingroff A. "Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009)". *Revista Iberoamericana de Micología* 26.1 (2006): 15-22.
16. Ashley E S D., et al. "Pharmacology of systemic antifungal agents". *Clinical Infectious Diseases* 43 (2006): S28-S39.
17. Gupta A K and Tomas E. "New antifungal agents". *Dermatologic Clinics* 21.3 (2003): 565-576.
18. Do J., et al. "Antifungal effects of cement mortars with two types of organic antifungal agents". *Cement and Concrete Research* 35.2 (2005): 371-376.
19. Goldstein A O and Goldstein BG. "Dermatophyte (tinea) infections". Waltham, MA: UpToDate, 26-29 (2017).

20. Bseiso E A., *et al.* "Recent advances in topical formulation carriers of antifungal agents". *Indian Journal of Dermatology, Venereology and Leprology* 81 (2015): 457.
21. Pereira PA., *et al.* "Superficial and cutaneous mycoses, epidemiology, virulence, susceptibility profile to antifungals and their infections: A literature review of the last twenty years". *International Journal of Pharmacy and Biological Sciences* 11.1 (2021): 176-187.
22. Schaller M., *et al.* "Topical antifungal-corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting". *Mycoses* 59.6 (2016): 365-373.
23. Santo R D. "Recent patents in antifungal agent discovery". *Expert Opinion on Therapeutic Patents* 18.3 (2008): 275-292.
24. Svetaz LA., *et al.* "Antifungal drugs combinations: a patent review 2000-2015". *Expert Opinion on Therapeutic Patents* 26.4 (2016): 439-453.
25. Nami S., *et al.* "Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases". *Biomedicine and Pharmacotherapy* 110 (2019): 857-868.
26. Kim J H., *et al.* "Advances in antifungal development: Discovery of new drugs and drug repurposing". *Pharmaceuticals* 15.7 (2022): 787.
27. Nawaz S., *et al.* "Biocompatible hydrogels for the controlled delivery of anti-hypertensive agent: Development, characterization and in vitro evaluation". *Designed Monomers and Polymers* 21.1 (2018): 18-32.
28. Stockman Kenneth E., *et al.* "Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices". U.S. Patent 9,393,344, issued July 19 (2016).
29. Gewehr M., *et al.* "Agricultural mixtures comprising carboxamide compound". United States patent application US 15/029,908. 2016 Aug 11 (2016).
30. El Mahrab Robert M and Kalia YN. "New developments in topical antifungal therapy". *American Journal of Drug Delivery* 4 (2006): 231-247.
31. Imran Mohd., *et al.* "Mucormycosis medications: a patent review". *Expert Opinion on Therapeutic Patents* 31.11 (2021): 1059-1074.
32. Class I P C and USPC A. Patent application title: Coatings and Surface Treatments Having Active Enzymes and Peptides Inventors: C. Steven Mcdaniel (Austin, TX, US) Assignees: REACTIVE SURFACES, LTD (2010).
33. Moriarity Branden., *et al.* "Tumor infiltrating lymphocytes and methods of therapy". U.S. Patent 10,912,797, issued February 9 (2021).
34. Salamone Joseph Charles., *et al.* "Delivery of biologically-active agents using volatile, hydrophobic solvents". U.S. Patent 8,852,648, issued October 7 (2014).
35. Kreutz T., *et al.* "Recent patents on permeation enhancers for drug delivery through nails". *Recent patents on drug delivery and formulation* 13.3 (2019): 203-218.
36. Svetaz LA., *et al.* "Antifungal drugs combinations review 2000-2015". *Expert Opinion on Therapeutic Patents* 26.4 (2016): 439-453.